drugset / Trial / NCT04470609
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years
Phase 1/2
Completed
471 enrolled
Institute of Medical Biology, Chinese Academy of Medical Sciences
West China Second University Hospital · collabYunnan Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study is a randomized, double-blinded, and placebo-controlled phase Ib/IIb clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged ⩾60 Years.
Timeline
- Start
- 2020-07-10
- Primary completion
- 2020-10-30
- Completion
- 2021-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | inactivated SARS-CoV-2 vaccine | Vaccine | 50 unknown | — |
| Subject | inactivated SARS-CoV-2 vaccine | Vaccine | 100 unknown | — |
| Subject | inactivated SARS-CoV-2 vaccine | Vaccine | 150 unknown | — |